BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 12010650)

  • 1. In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals.
    Klein R; Classen K; Berg PA; Lüdtke R; Werner M; Huber R
    Eur J Med Res; 2002 Apr; 7(4):155-63. PubMed ID: 12010650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a lectin- and a viscotoxin-rich mistletoe preparation on clinical and hematologic parameters: a placebo-controlled evaluation in healthy subjects.
    Huber R; Klein R; Berg PA; Lüdtke R; Werner M
    J Altern Complement Med; 2002 Dec; 8(6):857-66. PubMed ID: 12614536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of antibodies to viscotoxins A1, A2, A3, and B in tumour patients during therapy with an aqueous mistletoe extract.
    Klein R; Classen K; Fischer S; Errenst M; Scheffler A; Stein GM; Scheer R; von Laue HB
    Eur J Med Res; 2002 Aug; 7(8):359-67. PubMed ID: 12204844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic effects of mistletoe lectins: a placebo-controlled study in healthy subjects.
    Huber R; Rostock M; Goedl R; Lüdtke R; Urech K; Klein R
    J Soc Integr Oncol; 2006; 4(1):3-7. PubMed ID: 16737665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of anti-mistletoe lectin antibodies in relation to different mistletoe-extracts.
    Stein GM; Stettin A; Schultze J; Berg PA
    Anticancer Drugs; 1997 Apr; 8 Suppl 1():S57-9. PubMed ID: 9179370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of cellular and humoral immune responses during exposure of healthy individuals to an aqueous mistletoe extract.
    Stein GM; Berg PA
    Eur J Med Res; 1998 Jun; 3(6):307-14. PubMed ID: 9620894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study.
    Huber R; Lüdtke R; Klassen M; Müller-Buscher G; Wolff-Vorbeck G; Scheer R
    Eur J Med Res; 2001 Sep; 6(9):399-405. PubMed ID: 11669085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demonstration of antibodies to the chitin-binding mistletoe lectin (cbML) in tumor patients before and during therapy with an aqueous mistletoe extract.
    Klein R; Franz M; Wacker R; Classen K; Scheer R; Von Laue HB; Stoeva S; Voelter W
    Eur J Med Res; 2004 Jun; 9(6):316-22. PubMed ID: 15257874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
    Semiglazov VF; Stepula VV; Dudov A; Schnitker J; Mengs U
    Anticancer Res; 2006; 26(2B):1519-29. PubMed ID: 16619567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Frequency of the common cold in healthy subjects during exposure to a lectin-rich and a lectin-poor mistletoe preparation in a randomized, double-blind, placebo-controlled study].
    Huber R; Klein R; Lüdtke R; Werner M
    Forsch Komplementarmed Klass Naturheilkd; 2001 Dec; 8(6):354-8. PubMed ID: 11799303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro.
    Stettin A; Schultze JL; Stechemesser E; Berg PA
    Klin Wochenschr; 1990 Sep; 68(18):896-900. PubMed ID: 2124308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition of different antigens of mistletoe extracts by anti-mistletoe lectin antibodies.
    Stein GM; Pfüller U; Berg PA
    Cancer Lett; 1999 Jan; 135(2):165-70. PubMed ID: 10096425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
    Semiglasov VF; Stepula VV; Dudov A; Lehmacher W; Mengs U
    Anticancer Res; 2004; 24(2C):1293-302. PubMed ID: 15154663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viscotoxin-free aqueous extracts from European mistletoe (Viscum album L.) stimulate activity of human granulocytes.
    Stein GM; Pfüller U; Schietzel M
    Anticancer Res; 1999; 19(4B):2925-8. PubMed ID: 10652574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro immunoreactivity towards lectin-rich or viscotoxin-rich mistletoe (Viscum album L.) extracts Iscador applied to healthy individuals.
    Huber R; Classen K; Werner M; Klein R
    Arzneimittelforschung; 2006 Jun; 56(6A):447-56. PubMed ID: 16927525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial.
    Friess H; Beger HG; Kunz J; Funk N; Schilling M; Büchler MW
    Anticancer Res; 1996; 16(2):915-20. PubMed ID: 8687151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro.
    Stein G; Berg PA
    Eur J Clin Pharmacol; 1994; 47(1):33-8. PubMed ID: 7988621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial.
    Goebell PJ; Otto T; Suhr J; Rübben H
    J Urol; 2002 Jul; 168(1):72-5. PubMed ID: 12050495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection and quantitative determination of lectins and viscotoxins in mistletoe preparations].
    Jordan E; Wagner H
    Arzneimittelforschung; 1986 Mar; 36(3):428-33. PubMed ID: 3707660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of isolated mistletoe lectin chains in plant extracts.
    Tonevitsky AG; Marx U; Agapov I; Moisenovich M
    Arzneimittelforschung; 2002; 52(1):67-71. PubMed ID: 11838276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.